Skip to main content
NCBI home page
Gut logoLink to Gut
. 1984 Dec;25(12):1392–1398. doi: 10.1136/gut.25.12.1392

Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver.

L Fiume, A Mattioli, C Busi, C Accorsi
PMCID: PMC1420207  PMID: 6210232

Abstract

With the aim of improving the chemotherapeutic index of adenine arabinoside 5-monophosphate (ara-AMP) in the treatment of chronic hepatitis B, this drug was conjugated with lactosaminated serum albumin (L-SA), a neoglycoprotein which only enters into hepatocytes where it is digested in lysosomes. In mice, the L-[3H]SA-ara-AMP conjugates, intravenously injected, selectively penetrated the liver, only small quantities were taken up by cells of spleen, bone marrow, intestine, and brain. After administration of the conjugate to mice with Ectromelia virus hepatitis, ara-AMP was selectively concentrated in liver in a pharmacologically active form. If L-SA-ara-AMP conjugates behave in man as in mouse, their administration to patients with chronic hepatitis B should result in a selective concentration of ara-AMP in liver with a more efficient inhibition of virus replication accompanied by lower toxicity for other tissues.

Full text

PDF
1392

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashwell G., Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51:531–554. doi: 10.1146/annurev.bi.51.070182.002531. [DOI] [PubMed] [Google Scholar]
  2. BURTON K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956 Feb;62(2):315–323. doi: 10.1042/bj0620315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bassendine M. F., Chadwick R. G., Salmeron J., Shipton U., Thomas H. C., Sherlock S. Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology. 1981 May;80(5 Pt 1):1016–1022. [PubMed] [Google Scholar]
  4. Chadwick R. G., Bassendine M. F., Crawford E. M., Thomas H. C., Sherlock S. HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine. Br Med J. 1978 Aug 19;2(6136):531–533. doi: 10.1136/bmj.2.6136.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Derenzini M., Fiume L., Marinozzi V., Mattioli A., Montanaro L., Sperti S. Pathogenesis of liver necrosis produced by amanitin-albumin conjugates. Lab Invest. 1973 Aug;29(2):150–158. [PubMed] [Google Scholar]
  6. EDWARDS J. L., KLEIN R. E. Cell renewal in adult mouse tissues. Am J Pathol. 1961 Apr;38:437–453. [PMC free article] [PubMed] [Google Scholar]
  7. Fiume L., Busi C., Mattioli A., Balboni P. G., Barbanti-Brodano G. Hepatocyte targeting of adenine-9-beta-D-arabinofuranoside 5' -monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett. 1981 Jul 6;129(2):261–264. doi: 10.1016/0014-5793(81)80179-2. [DOI] [PubMed] [Google Scholar]
  8. Fiume L., Busi C., Mattioli A. Lactosaminated human serum albumin as hepatotropic drug carrier. Rate of uptake by mouse liver. FEBS Lett. 1982 Sep 6;146(1):42–46. doi: 10.1016/0014-5793(82)80701-1. [DOI] [PubMed] [Google Scholar]
  9. Fiume L., Busi C., Mattioli A. Targeting of antiviral drugs by coupling with protein carriers. FEBS Lett. 1983 Mar 7;153(1):6–10. doi: 10.1016/0014-5793(83)80108-2. [DOI] [PubMed] [Google Scholar]
  10. Fiume L., Mattioli A., Balboni P. G., Tognon M., Barbanti-Brodano G., de Vries J., Wieland T. Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett. 1979 Jul 1;103(1):47–51. doi: 10.1016/0014-5793(79)81247-8. [DOI] [PubMed] [Google Scholar]
  11. Fiume L., Mattioli A., Busi C., Balboni P. G., Barbanti-Brodano G., De Vries J., Altmann R., Wieland T. Selective inhibition of Ectromelia virus DNA synthesis in hepatocytes by adenine-9-beta-D-arabinofuranoside (ara-A) and adenine-9-beta-D-arabinofuranoside 5'-monophosphate (ara-AMP) conjugated to asialofetuin. FEBS Lett. 1980 Jul 28;116(2):185–188. doi: 10.1016/0014-5793(80)80639-9. [DOI] [PubMed] [Google Scholar]
  12. Fiume L., Mattioli A., Busi C., Spinosa G., Wieland T. Conjugates of adenine 9-alpha-D-arabinofuranoside monophosphate (ara-AMP) with lactosaminated homologous albumin are not immunogenic in the mouse. Experientia. 1982 Sep 15;38(9):1087–1089. doi: 10.1007/BF01955383. [DOI] [PubMed] [Google Scholar]
  13. Gray G. R. The direct coupling of oligosaccharides to proteins and derivatized gels. Arch Biochem Biophys. 1974 Jul;163(1):426–428. doi: 10.1016/0003-9861(74)90495-0. [DOI] [PubMed] [Google Scholar]
  14. Gregoriadis G. Targeting of drugs. Nature. 1977 Feb 3;265(5593):407–411. doi: 10.1038/265407a0. [DOI] [PubMed] [Google Scholar]
  15. Halloran M. J., Parker C. W. The preparation of nucleotide-protein conjugates: carbodiimides as coupling agents. J Immunol. 1966 Mar;96(3):373–378. [PubMed] [Google Scholar]
  16. JOKLIK W. K. The purification fo four strains of poxvirus. Virology. 1962 Sep;18:9–18. doi: 10.1016/0042-6822(62)90172-1. [DOI] [PubMed] [Google Scholar]
  17. Jentoft N., Dearborn D. G. Protein labeling by reductive alkylation. Methods Enzymol. 1983;91:570–579. doi: 10.1016/s0076-6879(83)91052-2. [DOI] [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. PLANTEROSE D. N., NISHIMURA C., SALZMAN N. P. The purification of vaccinia virus from cell cultures. Virology. 1962 Oct;18:294–301. doi: 10.1016/0042-6822(62)90016-8. [DOI] [PubMed] [Google Scholar]
  20. Plunkett W., Alexander L., Chubb S., Loo T. L. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo. Biochem Pharmacol. 1979;28(2):201–206. doi: 10.1016/0006-2952(79)90504-5. [DOI] [PubMed] [Google Scholar]
  21. Pollard R. B., Smith J. L., Neal A., Gregory P. B., Merigan T. C., Robinson W. S. Effect of vidarabine on chronic hepatitis B virus infection. JAMA. 1978 Apr 21;239(16):1648–1650. [PubMed] [Google Scholar]
  22. Regoeczi E. Hepatic uptake of asialoglycoproteins in vivo: quantification using a dual-isotope technique. J Nucl Biol Med. 1975 Jul-Sep;19(3):149–154. [PubMed] [Google Scholar]
  23. Sacks S. L., Scullard G. H., Pollard R. B., Gregory P. B., Robinson W. S., Merigan T. C. Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination. Antimicrob Agents Chemother. 1982 Jan;21(1):93–100. doi: 10.1128/aac.21.1.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sacks S. L., Smith J. L., Pollard R. B., Sawhney V., Mahol A. S., Gregory P., Merigan T. C., Robinson W. S. Toxicity of vidarabine. JAMA. 1979 Jan 5;241(1):28–29. doi: 10.1001/jama.1979.03290270020010. [DOI] [PubMed] [Google Scholar]
  25. Schneider W. C., Greco A. E. Incorporation of pyrimidine deoxyribonucleosides into liver lipids and other components. Biochim Biophys Acta. 1971 Feb 11;228(3):610–626. doi: 10.1016/0005-2787(71)90725-8. [DOI] [PubMed] [Google Scholar]
  26. Schwartz B. A., Gray G. R. Proteins containing reductively aminated disaccharides. Synthesis and chemical characterization. Arch Biochem Biophys. 1977 Jun;181(2):542–549. doi: 10.1016/0003-9861(77)90261-2. [DOI] [PubMed] [Google Scholar]
  27. Scullard G. H., Andres L. L., Greenberg H. B., Smith J. L., Sawhney V. K., Neal E. A., Mahal A. S., Popper H., Merigan T. C., Robinson W. S. Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside. Hepatology. 1981 May-Jun;1(3):228–232. doi: 10.1002/hep.1840010306. [DOI] [PubMed] [Google Scholar]
  28. Scullard G. H., Greenberg H. B., Smith J. L., Gregory P. B., Merigan T. C., Robinson W. S. Antiviral treatment of chronic hepatitis B virus infection: infectious virus cannot be detected in patient serum after permanent responses to treatment. Hepatology. 1982 Jan-Feb;2(1):39–49. doi: 10.1002/hep.1840020107. [DOI] [PubMed] [Google Scholar]
  29. Scullard G. H., Pollard R. B., Smith J. L., Sacks S. L., Gregory P. B., Robinson W. S., Merigan T. C. Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis. 1981 Jun;143(6):772–783. doi: 10.1093/infdis/143.6.772. [DOI] [PubMed] [Google Scholar]
  30. Smith C. I., Kitchen L. W., Scullard G. H., Robinson W. S., Gregory P. B., Merigan T. C. Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection. JAMA. 1982 Apr 23;247(16):2261–2265. [PubMed] [Google Scholar]
  31. Weller I. V., Bassendine M. F., Craxi A., Fowler M. J., Monjardino J., Thomas H. C., Sherlock S. Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP). Gut. 1982 Sep;23(9):717–723. doi: 10.1136/gut.23.9.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Whitley R., Alford C., Hess F., Buchanan R. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 1980 Oct;20(4):267–282. doi: 10.2165/00003495-198020040-00002. [DOI] [PubMed] [Google Scholar]
  33. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974 Sep 15;23(18):2495–2531. doi: 10.1016/0006-2952(74)90174-9. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES